MEK inhibitors for the treatment of non-small cell lung cancer

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the pro...

Source: Journal of Hematology and Oncology - January 5, 2021 Category: Hematology Authors: Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li and Qiming Wang Tags: Review Source Type: research